elvucitabine
Small moleculeexperimental
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV infection. — Wikipedia
Clinical trial activity
8 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2002 (NCT00034359)
Timeline
Indications
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
- DNA polymerase/reverse transcriptaseINHIBITOR
DNA polymerase/reverse transcriptase inhibitor
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(=O)n([C@@H]2C=C[C@H](CO)O2)cc1F- Mol. weight
- 227.19 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaElvucitabine ↗
- ChEMBLCHEMBL38700 ↗
Also known as
- ach-126443
- ach-126443
- ach-126-443
- ach126-443
- beta-l-fd4c
- beta-l-fd4c
- beta-l-fd4c
- elvucitabine
- elvucitabine
- elvucitabine
- elvucitabine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00675844 | Phase 2 | May 1, 2008 | Achillion Pharmaceuticals, Bellos, Nicholaos C., M.D., Central Texas Primary Care Research Network, Orlando Immunology Center |
| NCT00380159 | Phase 2 | Sep 1, 2006 | Achillion Pharmaceuticals, AIDS Research Consortium of Atlanta, Icahn School of Medicine at Mount Sinai, Orlando Immunology Center, University of Alabama, University of California, Davis, University of Cincinnati, University of Miami |
| NCT00405249 | Phase 2 | Sep 1, 2006 | Thomas Jefferson University |
| NCT00350272 | Phase 2 | May 1, 2006 | Achillion Pharmaceuticals |
| NCT00312039 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2006 | Achillion Pharmaceuticals, Icahn School of Medicine at Mount Sinai, Orlando Immunology Center, University of Alabama, Birmingham, University of California, Davis, University of Cincinnati, University of Miami |
| NCT00040157 | Phase 2 | Jun 21, 2002 | Achillion Pharmaceuticals |
| NCT00037622 | N/A | May 17, 2002 | Achillion Pharmaceuticals |
| NCT00034359 | Phase 2 | Feb 1, 2002 | Achillion Pharmaceuticals |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Achillion Pharmaceuticals | For profit | 7 | 7 | 2 | 2002 |
| Orlando Immunology Center | Academic/Hospital | 3 | 0 | 1 | 2006 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 2 | 0 | 1 | 2006 |
| University of California, Davis | Academic/Hospital | 2 | 0 | 1 | 2006 |
| University of Cincinnati | Academic/Hospital | 2 | 0 | 1 | 2006 |
| University of Miami | Academic/Hospital | 2 | 0 | 1 | 2006 |
| AIDS Research Consortium of Atlanta | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Bellos, Nicholaos C., M.D. | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Central Texas Primary Care Research Network | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Thomas Jefferson University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| University of Alabama | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2006 |
12 organizations
Page 1 / 1